Close Menu

NEW YORK – Agios Pharmaceuticals said on Monday that it has entered into a definitive agreement to sell its oncology portfolio to global pharmaceutical firm Servier for $1.8 billion upfront so that it can focus on developing treatments for genetically defined diseases.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.